StreetInsider.com News Articles

Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC

Fri, 14 Aug 2026 13:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26928291.html

Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC

Fri, 14 Aug 2026 13:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26928291.html

Mizuho sees a chance to buy this biotech stock after recent weakness

Fri, 14 Aug 2026 13:00:00 -0400

Shares in one U.S. biotech firm have fallen more than 30% since late June, compared with a 0.1% decline in the XBI biotech index, after concerns emerged around the manufacturing of one of its lead drug candidates.

However, an analyst at Mizuho thinks the sell-off is overdone and has reiterated an Outperform rating.

The company is Relmada Therapeutics (NASDAQ: RLMD), whose experimental bladder cancer treatment NDV-01 has been at the center of investor concern following news of a manufacturing delay.

After connecting with management, Mizuho analyst Uy Ear said he believes the delay "is manageable as it stems from an operational

Mizuho sees a chance to buy this biotech stock after recent weakness

Fri, 14 Aug 2026 13:00:00 -0400

However, an analyst at Mizuho thinks the sell-off is overdone and has reiterated an Outperform rating.

The company is Relmada Therapeutics (NASDAQ: RLMD), whose experimental bladder cancer treatment NDV-01 has been at the center of investor concern following news of a manufacturing delay.

After connecting with management, Mizuho analyst Uy Ear said he believes the delay "is manageable as it stems from an operational

Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)

Tue, 11 Aug 2026 05:10:12 -0400

Mizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD)

The analyst comments "Concerns surrounding NDV-01 manufacturing have driven a significant sell-off with RLMD down ~35% (vs. -0.1% XBI) since June 30 when these concerns emerged. We believe the reaction is overdone. We connected with management and believe the manufacturing delay is manageable as it stems from an operational scheduling constraint at Relmada's CMO that has delayed the start of NDV-01's GMP production. Our manufacturing expert indicated this is a common issue at CMOs. Importantly, the key technical manufacturing components are completed and

Relmada Therapeutics (RLMD) Tops Q2 EPS by 8c

Thu, 06 Aug 2026 17:05:31 -0400

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.11), $0.08 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

Form 8-K RELMADA THERAPEUTICS, For: Aug 06

Thu, 06 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26884987.html

Form 8-K RELMADA THERAPEUTICS, For: Aug 06

Thu, 06 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26884987.html

Form 10-Q RELMADA THERAPEUTICS, For: Jun 30

Thu, 06 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26884216.html

Form 10-Q RELMADA THERAPEUTICS, For: Jun 30

Thu, 06 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26884216.html

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.
Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.
Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.
Added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Management to host a conference

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:22:00 -0400
si-local-file:///var/storage/secattach/20260729/26834343.html

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:22:00 -0400
si-local-file:///var/storage/secattach/20260729/26834343.html

Form 8-K RELMADA THERAPEUTICS, For: Jul 28

Tue, 28 Jul 2026 08:36:00 -0400
si-local-file:///var/storage/secattach/20260728/26823120.html

Form 8-K RELMADA THERAPEUTICS, For: Jul 28

Tue, 28 Jul 2026 08:36:00 -0400
si-local-file:///var/storage/secattach/20260728/26823120.html

Relmada Therapeutics names Bipin Dalmia as chief business officer

Tue, 28 Jul 2026 08:31:01 -0400

Relmada Therapeutics, Inc. (Nasdaq: RLMD) has appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer, according to a company statement. Dalmia will oversee corporate strategy, commercial planning, and business development, reporting to Chief Executive Officer Sergio Traversa.
Dalmia brings nearly three decades of biopharmaceutical experience, with a focus on non-muscle invasive bladder cancer (NMIBC) and business development. He most recently served as Senior Vice President, Global Head of Portfolio Strategy and Business Development at Ferring Pharmaceuticals, where he spent 14 years. During that time, he led the company's Uro-Oncology Franchise, including the U.S. launch of ADSTILADRIN, which the Food and Drug

Relmada Therapeutics names Bipin Dalmia as chief business officer

Tue, 28 Jul 2026 08:31:01 -0400

Relmada Therapeutics, Inc. (Nasdaq: RLMD) has appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer, according to a company statement. Dalmia will oversee corporate strategy, commercial planning, and business development, reporting to Chief Executive Officer Sergio Traversa.
Dalmia brings nearly three decades of biopharmaceutical experience, with a focus on non-muscle invasive bladder cancer (NMIBC) and business development. He most recently served as Senior Vice President, Global Head of Portfolio Strategy and Business Development at Ferring Pharmaceuticals, where he spent 14 years. During that time, he led the company's Uro-Oncology Franchise, including the U.S. launch of ADSTILADRIN, which the Food and Drug

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

Tue, 28 Jul 2026 08:30:00 -0400

Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation.

CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bipin will lead Relmada's corporate strategy, commercial planning, and business development activities, reporting